A renewed call for cheap tests that can rapidly identify resistant forms of the disease.

According to the District Health Barometer, TB and HIV are still the main causes of death. But the Barometer reveals that some districts have shown great improvements in tackling these diseases.

Updated WHO guidance launched today scales up effective public health interventions to reduce TB deaths for people living with HIV.

Dudley Lee's case reveals how overcrowding and a struggling court system are fuelling a TB epidemic.

A new paper outlining the pressing need for more advocacy efforts to address childhood TB has been published in the European Respiratory Journal.

The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) agrees with the World Health Organization (WHO) dosing recommendations for ethambutol, isoniazid, pyrazinamide, and rifampicin as first-line antituberculosis medicines used in children, according to new EMA dosing guidelines released February 17.

TB/HIV co-infection represents a novel pathogenic scenario at the global level. Our knowledge about the mechanisms of interaction of the two pathogens still has many gaps that need to be filled in order to develop preventive measures against the two diseases.

Treatment Action Group (TAG) is deeply disappointed by President Obama’s proposed cuts to PEPFAR (President’s Emergency Plan for AIDS Relief) and bilateral TB funds, freezing of NIH (National Institutes of Health) research as well as the insufficient attention to the worsening domestic AIDS crisis in the administration's fiscal year 2013 budget plan.

We need a new vision for TB writes AIDS and TB activist Mark Harrington, Executive Director of the Treatment Action Group.

Two experimental drugs for the treatment of MDR TB have completed phase II clinical trials.